NanoString announces publication of clinical study for Prosigna breast cancer assay
NanoString announced publication of a study in Clinical Cancer Research that reinforces the ability of the company's Prosignaź Breast Cancer Assay to inform physician treatment decisions by predicting which patients are most likely to benefit from chemotherapy. July 07, 2015